BridgeMD
New treatment option for Gambling Disorder
Official title Virtual Reality Exposure Therapy for Gambling Disorder
ClinicalTrials.gov ID: NCT04467502
What this study is testing
- What it's testing
- Gambling disorder (GD) is recognized as an addictive disorder in the DSM-5. Craving is a core phenomenon in addiction that can lead to relapse in problem gambling for pathological gamblers.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Seek treatment for GD within one of health care facilities participating in the research (first request for treatment and not patients already...
- Meet a current diagnosis of gambling disorder according to DSM-5 criteria and with a South Oaks Gambling Screen (SOGS) score ≥ 5
- Meet a casino gambling behavior with a casino gambling frequency ≥ 1 time every two months during the last 12 months
- Have a sufficient understanding of French for therapy
- Beneficiary of the French social security system
You likely can't join if
- Visual disturbance making impossible the use of virtual reality equipment (e.g. advanced retinal degeneration, central scotoma, age-related macular...
- Pregnant woman
- Minor or adult under guardianship, conservatorship, under judicial protection, persons deprived of their liberty
- Balance disorder (e.g. cerebellar disorder, inner ear disorder)
- Photosensitive epilepsy
- Refusal to participate
See the full eligibility criteria
- Seek treatment for GD within one of health care facilities participating in the research (first request for treatment and not patients already receiving treatment for gambling disorder in the care center).
- Meet a current diagnosis of gambling disorder according to DSM-5 criteria and with a South Oaks Gambling Screen (SOGS) score ≥ 5
- Meet a casino gambling behavior with a casino gambling frequency ≥ 1 time every two months during the last 12 months
- Have a sufficient understanding of French for therapy
- Beneficiary of the French social security system
- Give an informed consent to participate
- Willing to comply with all study procedures and duration
- Visual disturbance making impossible the use of virtual reality equipment (e.g. advanced retinal degeneration, central scotoma, age-related macular degeneration)
- Pregnant woman
- Minor or adult under guardianship, conservatorship, under judicial protection, persons deprived of their liberty
- Balance disorder (e.g. cerebellar disorder, inner ear disorder)
- Photosensitive epilepsy
- Refusal to participate
The study team makes the final eligibility decision.
Where it's taking place
- Amiens, France
- Boulogne-sur-Mer, France
- Caen, France
- Lille, France
- Lomme, France
- Montreuil-sur-Mer, France
- Rouen, France
- Saint-Amand-les-Eaux, France
- Seclin, France
- Valenciennes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amiens, France; Boulogne-sur-Mer, France; Caen, France; Lille, France; Lomme, France; Montreuil-sur-Mer, France and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.